
Gen Z Wants To Own Homes—So Why Is It Still Out of Reach for Most?
Gen Z is falling behind on the path to homeownership. In 2025, they made up just 3% of all homebuyers, according to the National Association of Realtors®, the smallest share of any generation and a sharp contrast to baby boomers, who accounted for 42% of buyers.
While high interest rates and higher home prices have made it harder for young adults to break into the market, new research suggests another force might be working against Gen Z: how they manage their money.
Advertisement
According to PYMNTS Intelligence, a payments data provider, despite valuing homeownership, Gen Z's top financial goal isn't buying a home. It's paying off debt.
The average Gen Z adult carries an average of $94,101 in personal debt, with credit card debt being the most common.
With so much of their income tied up in monthly payments, even high earners in this generation are struggling to save for a down payment or qualify for a mortgage. Debt, not disinterest, might be the real reason Gen Z is falling behind—at least for now.
4 Gen Z's biggest financial concern is how they are going to pay off their debt.
Getty Images
Advertisement
'Though Gen Z Americans may dream of homeownership, still-high housing costs mean that stepping onto the property ladder may not be possible at this point in time,' says Hannah Jones, senior economic research analyst at Realtor.com®. 'By prioritizing paying off debt, Gen Z prospective buyers are setting themselves up for success when homeownership does become more feasible.'
The 2 financial personas and where Gen Z fits in
PYMNTS Intelligence identifies two key money management mindsets:
Planners , who proactively save and pay off credit cards
, who proactively save and pay off credit cards Reactors, who handle bills as they come and often rely on credit or loans
Advertisement
Gen Z overwhelmingly falls into the latter group. A striking 73% of Gen Zers are classified as reactors, making them more likely to live paycheck to paycheck, carry high-interest debt, and struggle to build savings. That reactive approach can seriously undermine major financial goals, like buying a home, because it prioritizes short-term survival over long-term stability.
Even more surprising, the reactor mindset is gaining ground among high earners across generations. Since February 2024, the share of six-figure earners who identify as planners has dropped by 25%. Now, 52% of top earners are reactors, a shift that underscores how widespread short-term financial thinking has become, even among those typically viewed as having the means to plan ahead
4 Even high earners in this generation are struggling to save for a down payment or qualify for a mortgage.
Getty Images/iStockphoto
Risk over security: The Gen Z money mindset
Unlike baby boomers, 54% of whom are planners focused on long-term stability, Gen Z is chasing growth. According to the PYMNTS report:
Advertisement
Just 7.7% of Gen Z cite retirement saving as a top financial priority, compared with 22.1% of baby boomers.
Nearly 7% of Gen Z say their No. 1 goal is starting a business, making them eight times more likely than boomers to focus on entrepreneurship.
'Gen Z Americans have time on their side and may be more willing to take big swings financially, while older generations are more risk-averse,' says Jones.
While starting a business can lead to long-term wealth, it typically comes with short-term financial instability, exactly what makes it harder to qualify for a mortgage or build up a down payment.
Irregular income, high credit utilization, and limited savings make it much harder to qualify for a mortgage under traditional lending models. Even high-earning Gen Z entrepreneurs might struggle to demonstrate the consistent income or financial reserves lenders expect.
This risk-oriented mindset might be a reaction to the current conditions of the housing market. Buyers now need to earn 70% more than they did just six years ago to buy a home, to say nothing of the difference between buying a house now than in the 1960s and '70s, when many baby boomers bought their first homes. These conditions have made many in Gen Z feel that shooting for the moon in business is a more realistic goal than saving for that white picket fence.
4 Gen Z is more willing to take risks than previous generations.
Getty Images/iStockphoto
Why buying a home is still a priority—just not the first one
Homeownership hasn't fallen off Gen Z's radar, but it's taking a back seat to paying off existing debt. Buying a house ranks as this generation's second most important financial goal, with 14.1% of Gen Zers ranking it as a priority.
But deprioritizing homeownership, even temporarily, can come at a long-term cost. In a market where prices keep climbing, every year spent focusing elsewhere can make the eventual buy-in more expensive. And because lenders heavily weigh savings, credit usage, and income consistency, Gen Z's current financial behaviors—like revolving debt and low reserves—can delay homeownership even further, regardless of intent or income.
Advertisement
In other words, Gen Z still wants to own, but the reactive financial path they're following makes it harder to get there. Without a shift in priorities, many might find themselves stuck in a cycle where the dream of owning a home never quite catches up to their ambition.
4 The generation is mostly concerned with first paying off existing debt, putting homeownership on the back burner.
Getty Images
What Gen Z can do differently
To bridge the gap between ambition and ownership, Gen Z might need to rethink how they prioritize and manage their money. The good news is that paying off debt, Gen Z's top financial priority, will eventually help them buy a house by lowering their debt-to-income ratio.
The area where they can make the biggest changes, though, is in moving from a reactive mindset to a planning mindset. Here's how they can get started:
Advertisement
Automate savings to gradually build up a down payment.
Track spending patterns to identify areas to cut back.
Use credit strategically, aiming to pay in full each month.
Pursue both goals in parallel—treat debt repayment as a priority, but not at the cost of building a safety net to support future homeownership.
Gen Z hasn't turned away from homeownership, but when the top priority involves risk or volatility, it can make the second one harder to reach. With the right habits and tools, Gen Z can build both the freedom to pursue big dreams and the foundation to one day own a piece of them.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Entrepreneur
an hour ago
- Entrepreneur
სელფი მობაილი ZEG ფესტივალის პარტნიორია
საავტორო უფლება © 2025 Entrepreneur Media, LLC ყველა უფლება დაცულია. Entrepreneur® and its related marks are registered trademarks of Entrepreneur Media LLC


The Hill
an hour ago
- The Hill
Republicans lay groundwork for ‘total tax cliff' at end of Trump's term
Congressional Republicans are laying the groundwork for a tax cliff at the end of President Trump's term in office. While the conference is pushing to make the 2017 Trump tax cuts permanent, additional measures geared toward working-class Americans are being slated for expiration at the end of 2028. 'It means that's going to be an issue in the next presidential race,' House Freedom Caucus Chair Andy Harris (R-Md.) said Tuesday. The major expiring tax breaks in the House-passed version of Republicans' domestic agenda bill are boosts in the standard deduction, the deduction for seniors, and the child tax credit, along with the cancellation of taxes on tips, overtime pay, and car loan interest. Budget hawks are saying this sets up a 'tax cliff' in the legislation similar to the one Republicans are now trying to surmount, since most of the 2017 Trump tax cuts expire at the end of this year. 'There's a total tax cliff in there. There's about $1.5 trillion worth of taxes that expire in four years, five years, which means what? In five years, they'll just keep them going. This is why we end up with the same problem,' Rep. Chip Roy (R-Texas) said last week. 'It is 100 percent a gimmick to have tax cuts that you're putting in place for four or five years,' he added. The legislation is likely to undergo substantial changes in the Senate, including a change in the accounting baseline that will allow trillions of dollars worth of deficit additions coming from the extension of previous tax cuts to be ignored. But senators are sounding open to maintaining the split between making the 2017 Tax Cuts and Jobs Act (TCJA) permanent and allowing the additional cuts for workers, families, retirees and consumers to expire. 'The general feeling of Senate Finance is the TCJA — we need to make that permanent. We need to make the business provisions — the expensing, the R&D provisions — we need to make those permanent. The other things, I think we should discuss it,' Sen. Ron Johnson (R-Wis.), a member of the Senate Finance Committee, said last week. Sen. John Hoeven (R-N.D.) stressed the objective of overall permanence while saying the additional cuts could be subject to change. 'Our intent is to make the tax cuts permanent. Now, something like the child tax credit, with a huge transfer payment aspect to it, I'd have to say that's something I'd have to check on. Other tax cuts and reductions, depending on score and how the votes come down, that could change,' he said last week. The expiring cuts are mostly ones that were proposed by President Trump while he was on the campaign trail. They appealed to various constituencies and came fast and furious in the run-up to the election. Seven different targeted tax proposals were floated in September and October, according to a tally by news agency Reuters. Trump proposed making auto loan interest fully deductible at a speech in October in Detroit, the capital of the U.S. auto industry. He pitched getting rid of taxes on tips in June in Las Vegas, Nev., a battleground state with an enormous hospitality sector. He proposed a tax credit for family caregivers at a rally at Madison Square Garden in New York, a state where more than 4 million people take care of loved ones. Many in the policy establishment — both left-leaning and right-leaning — view Trump's additional cuts as ancillary, if not altogether undesirable. 'I would prefer those things would be completely off the list,' Daniel Bunn, president of the Tax Foundation, a conservative think tank in Washington, told The Hill in November. 'It's not good policy. It does not move in the same direction that the 2017 reforms work.' William Gale, co-director of the more liberal Urban-Brookings Tax Policy Center, wrote in a commentary last year that canceling taxes on tips was a bad idea. 'The obvious problem is that the proposals are inconsistent with sound tax policy. The less obvious problem is that exempting tips would not even help the vast majority of low-income workers,' he wrote. While senators sound open to keeping the division between permanent and temporary tax cuts, they're also wary about creating another tax cliff that is likely to factor into political debates in the future. 'They're doing that for only four years, and all of a sudden that stops? I'm not real high on tax policy that expires,' Johnson said of the no-tax-on-tips provision. 'If it's good enough to include, let's make it permanent. Let's have that discussion.' The Senate has a lot more room to work with than the House since its budget baseline for the bill could allow about $5.5 trillion in expiring tax cuts to be left out of the accounting. However, conservatives in both chambers have expressed concerns about the potential deficit impact of the GOP bill, which has rattled financial markets and spurred a sell-off in the bond market. The nonpartisan Congressional Budget Office (CBO) estimated last week that the House's version of the plan would add $2.4 trillion to the nation's deficits over roughly the next decade. In a follow-up analysis requested by Democrats, Congress' official budget scorer estimated additional interest costs resulting from the plan would amount to $551 billion over a decade — a change that would 'increase the cumulative effect on the deficit to $3.0 trillion.' While top Republicans have sought to discredit the CBO's scoring of the measure, there has been distress in both chambers, as well as the White House, over the overall cost and the fact that it is projected to grow the economy by just 0.03 percent. The Joint Committee on Taxation (JCT) estimated that the bill would grow the economy from 1.83 percent to 1.86 percent over the long run, representing little change from the Federal Reserve's latest prediction of 1.8 percent made prior to the passage of the legislation in the House. 'The Democrat inspired and 'controlled' Congressional Budget Office (CBO) purposefully gave us an extremely low level of growth, 1.8 percent over 10 years — how ridiculous and unpatriotic is that!' Trump wrote on social media earlier this month. One of JCT's models shows the legislation reducing U.S. capital stock by 0.9 percent over the budget window, leading to an overall decrease in economic output. 'The first and second half effects result in a decrease of 0.1 percent on average over the entire budget window,' JCT found. Democrats have seized upon the expiring cuts that Trump proposed as evidence that the bill is skewed toward the wealthy — though lower income tax rates for lower earners will be made permanent as part of the bill. 'Why is this bill designed to take away some of the benefits that you claim people are going to have?' Rep. Gwen Moore (D-Wis.) asked Treasury Secretary Scott Bessent during a hearing Wednesday. 'The senior tax credit expires … No taxes on tips expires.' Despite locking in lower tax rates for lower earners, forecasts project the House-passed tax bill will benefit higher earners more and will redistribute wealth from the bottom to the top of the income spectrum. Half of the bill's passthrough deduction alone, which was worth more than $200 billion in 2022, went to the top 1 percent of taxpayers by adjusted gross income, according to the JCT.
Yahoo
an hour ago
- Yahoo
ADC Therapeutics Announces Updated Data from LOTIS-7 Clinical Trial Presented at the European Hematology Association 2025 Congress
ZYNLONTA® in combination with glofitamab (COLUMVI®) in patients with r/r DLBCL demonstrated clinically meaningful benefit with overall response rate (ORR) of 93.3% and a complete response (CR) rate of 86.7% across 30 efficacy evaluable patients 25 of 26 patients achieving CR remained in CR as of the data cut-off Initial data show the combination is generally well tolerated with a manageable safety profile Company expanding enrollment for LOTIS-7 to 100 patients at 150 µg/kg dose Company to host conference call today at 8:00 a.m. ET/2:00 p.m. CEST LAUSANNE, Switzerland, June 12, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced updated data from the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA® in combination with the bispecific antibody glofitamab (COLUMVI®) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) to be presented at the European Hematology Association 2025 Congress (EHA2025) in Milan, Italy. The Company will host a conference call and webcast featuring LOTIS-7 trial principal investigator and EHA presenting author, Juan Alderuccio, MD, Clinical Site Disease Group Leader, Lymphoma Section, at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine today at 8:00 a.m. ET to discuss the results. To access the conference call, please register here. "The data seen in this study with the combination of ZYNLONTA and glofitamab has shown a manageable safety profile along with strong efficacy data from patients with relapsed or refractory DLBCL, with complete responses observed regardless of prior therapy, including CAR-T," said Mohamed Zaki, MD, PhD, Chief Medical Officer of ADC Therapeutics. "The combination of these two anti-cancer agents holds significant promise for advancing the treatment landscape and addressing unmet need in patients with these hard-to-treat lymphomas." The presentation highlights updated data as of April 14, 2025, in which r/r LBCL patients received dose levels of 120 µg/kg or 150 µg/kg of ZYNLONTA plus the bispecific antibody glofitamab, with 41 patients evaluable for safety and 30 patients evaluable for efficacy. Key highlights of the LOTIS-7 data presentation are as follows: Best overall response data among the 30 efficacy evaluable patients shows overall response rate (ORR) of 93.3% (28/30 pts) as assessed by Lugano Criteria Complete response (CR) rate of 86.7% (26/30 pts) Of these, 25/26 patients achieving CR remain in CR as of the data cut-off Median time to CR in 120 µg/kg = 80 days Median time to CR in 150 µg/kg = 42 days 12 patients converted from stable disease (SD) or partial response (PR) to CR over time (1 and 11 pts respectively) Of the 6 patients previously treated with CAR-T and undergoing response assessment, 5 achieved a CR Among the 41 safety evaluable patients, the combination was generally well tolerated with a manageable safety profile and no DLTs across dose levels Grade 3 or higher treatment emergent adverse events (TEAEs) observed in > 5% of patients included neutropenia (24.4%), anemia (9.8%), AST increased (7.3%), GGT increased (7.3%), and thrombocytopenia (7.3%) In the 150 µg/kg dose, cytokine release syndrome (CRS) (23.8%), all of which were Grade 1, and immune effector cell-associated neurotoxicity syndrome (ICANS) (4.8%), with one case of Grade 2, were observed In the 120 µg/kg dose, CRS all grades (55%), all of which were Grade 1/2 except one case of Grade 3, and ICANS (10%), with one case of Grade 1 and one case of Grade 2, were observed TEAEs leading to discontinuation included 3 each for ZYNLONTA and glofitamab There were no Grade 5 TEAEs observed "We believe these new data are differentiating and further reinforce the potential of ZYNLONTA plus the bispecific glofitamab to improve outcomes for DLBCL patients who need it most," said Ameet Mallik, Chief Executive Officer of ADC Therapeutics. "This early safety and efficacy data support the ongoing expansion of this study to 100 patients at the 150 µg/kg dose of ZYNLONTA plus glofitamab. We look forward to discussing the results with Dr. Alderuccio during our conference call today in addition to the presentation of the data set across two key conferences." This data will be shared at EHA2025 during a poster presentation on June 14 at 6:30 p.m. CEST and also as an oral encore presentation at the 18th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland on Friday, June 20 at 9:00 a.m. ET. The Company plans to share additional data before the end of 2025. Conference Call InformationTo access the conference call, please register here. The participant toll-free dial-in number is 1-800-836-8184 for North America and Canada. It is recommended that you join 10 minutes before the event, though you may pre-register at any time. A live webcast of the call will be available under "Events and Presentations" in the Investors section of the ADC Therapeutics website at The archived webcast will be available for 30 days following the call. About LOTIS-7LOTIS-7 is a Phase 1b global multicenter, multi-arm study in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) including Part 1 (dose escalation) and Part 2 (dose expansion). The three dosing arms include ZYNLONTA plus polatuzumab vedotin, ZYNLONTA plus glofitamab, and ZYNLONTA plus mosunetuzumab T-cell-engaging bispecific monoclonal antibodies (BsAbs). Enrollment in LOTIS-7 includes Part 1 of the study with a 3+3 dose escalation in 3L/3L+ heavily pre-treated patients with ZYNLONTA doses starting at 90 µg/kg and then proceeding to 120 µg/kg and 150 µg/kg. Part 2 includes dose expansion in 2L/2L+ large B-cell lymphoma in the ZYNLONTA plus glofitamab arm at dose levels determined from Part 1 (120 µg/kg and 150 µg/kg of ZYNLONTA plus the approved dosing of glofitamab). Primary endpoints of the study include safety and tolerability. Secondary efficacy endpoints include ORR, DOR, CRR, PFS, RFS, and OS as well as pharmacokinetics and immunogenicity. For more information about the LOTIS-7 trial, visit (NCT04970901). About ZYNLONTA® ZYNLONTA® is a CD19-directed antibody drug conjugate (ADC). Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload. The potent payload binds to DNA minor groove with little distortion, remaining less visible to DNA repair mechanisms. This ultimately results in cell cycle arrest and tumor cell death. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved ZYNLONTA (loncastuximab tesirine-lpyl) for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from low-grade lymphoma and also high-grade B-cell lymphoma. The trial included a broad spectrum of heavily pre-treated patients (median three prior lines of therapy) with difficult-to-treat disease, including patients who did not respond to first-line therapy, patients refractory to all prior lines of therapy, patients with double/triple hit genetics and patients who had stem cell transplant and CAR-T therapy prior to their treatment with ZYNLONTA. This indication is approved by the FDA under accelerated approval and in the European Union under conditional approval based on overall response rate and continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Please see full prescribing information including important safety information about ZYNLONTA at ZYNLONTA is also being evaluated as a therapeutic option in combination studies in other B-cell malignancies and earlier lines of therapy. About ADC Therapeutics ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company helping to improve the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development. ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and has operations in London and New Jersey. For more information, please visit and follow the Company on LinkedIn. ZYNLONTA® is a registered trademark of ADC Therapeutics SA. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the potential of ZYNLONTA® in combination with the bispecific antibody glofitamab, including the reproducibility and durability of any favorable results initially seen in patients dosed to date, and the Company's research, development and regulatory plans, including the timing and results of clinical trials and the timing and outcome of regulatory submissions. In some cases you can identify forward-looking statements by terminology such as "may", "will", "should", "would", "expect", "intend", "plan", "anticipate", "believe", "estimate", "predict", "potential", "seem", "seek", "future", "continue", or "appear" or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: whether future LOTIS-7 clinical trial results will be consistent with or different from the LOTIS-7 data presented at EHA and ICML and future compendia and regulatory strategy and opportunity; the expected cash runway into mid-2026 the Company's ability to grow ZYNLONTA® revenue in the United States; the ability of our partners to commercialize ZYNLONTA® in foreign markets, the timing and amount of future revenue and payments to us from such partnerships and their ability to obtain regulatory approval for ZYNLONTA® in foreign jurisdictions; the timing and results of the Company's or its partners' research and development projects or clinical trials including LOTIS 5 and 7, as well as early research in certain solid tumors with different targets, linkers and payloads; the timing and results of investigator-initiated trials including those studying FL and MZL and the potential regulatory and/or compendia strategy and the future opportunity; the timing and outcome of regulatory submissions for the Company's products or product candidates; actions by the FDA or foreign regulatory authorities; projected revenue and expenses; the Company's indebtedness, including Healthcare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company's activities by such indebtedness, the ability to comply with the terms of the various agreements and repay such indebtedness and the significant cash required to service such indebtedness; and the Company's ability to obtain financial and other resources for its research, development, clinical, and commercial activities. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K and in the Company's other periodic and current reports and filings with the U.S. Securities and Exchange Commission. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. CONTACTS:Investor RelationsMarcy GrahamADC 650-667-6450 Media RelationsNicole RileyADC 862-926-9040 View original content to download multimedia: SOURCE ADC Therapeutics SA Sign in to access your portfolio